Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + interferon alfa-2a
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Pazopanib + interferon alfa-2a is a combination of two agents with antineoplastic and immunomodulatory properties. Pazopanib is a small molecule, orally available, multitargeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), and vascular endothelial growth factor receptor 3 (VEGFR3); platelet-derived growth factor receptor alpha (PDGFRα) and platelet-derived growth factor receptor beta (PDGFRβ); and mast/stem cell growth factor receptor Kit (c-kit). This inhibition disrupts angiogenesis pathways critical for tumor blood vessel formation, leading to reduced tumor growth and survival[1][4][6]. Interferon alfa-2a is a recombinant protein form of human type I interferon that binds to type I interferon receptor (IFNAR), activating the JAK/STAT pathway to induce antiviral proteins and modulate immune responses. It has been used as an antiviral or antineoplastic agent in various cancers and viral infections[2][8]. The combination may be explored for synergistic effects in oncology by combining antiangiogenic activity with immune modulation.
- Brand names
- VotrientRoferon-A
- Other names
- interferon alpha 2arecombinant human interferon alpha 2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)BRAF (B-Raf proto-oncogene, serine/threonine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on pazopanib + interferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + interferon alfa-2a.